nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Dactinomycin—skin cancer	0.243	0.534	CbGbCtD
Amphetamine—CYP2A6—Fluorouracil—skin cancer	0.125	0.274	CbGbCtD
Amphetamine—CYP2D6—Vemurafenib—skin cancer	0.0875	0.192	CbGbCtD
Amphetamine—CARTPT—nerve—skin cancer	0.0242	0.168	CbGeAlD
Amphetamine—MAOB—Dopamine metabolism—TYR—skin cancer	0.0173	0.194	CbGpPWpGaD
Amphetamine—TAAR1—neck—skin cancer	0.0136	0.0946	CbGeAlD
Amphetamine—Monobenzone—TYR—skin cancer	0.0128	0.863	CrCbGaD
Amphetamine—CARTPT—connective tissue—skin cancer	0.00975	0.0678	CbGeAlD
Amphetamine—Cardiomyopathy—Imiquimod—skin cancer	0.0078	0.0263	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—NKX2-1—skin cancer	0.00753	0.0844	CbGpPWpGaD
Amphetamine—CARTPT—lymphoid tissue—skin cancer	0.00713	0.0496	CbGeAlD
Amphetamine—TAAR1—female reproductive system—skin cancer	0.00688	0.0478	CbGeAlD
Amphetamine—CARTPT—female reproductive system—skin cancer	0.00688	0.0478	CbGeAlD
Amphetamine—SLC6A3—nerve—skin cancer	0.00623	0.0433	CbGeAlD
Amphetamine—Tooth disorder—Imiquimod—skin cancer	0.00615	0.0208	CcSEcCtD
Amphetamine—CARTPT—head—skin cancer	0.00575	0.0399	CbGeAlD
Amphetamine—MAOB—nerve—skin cancer	0.00542	0.0377	CbGeAlD
Amphetamine—Abdominal pain upper—Vismodegib—skin cancer	0.00502	0.0169	CcSEcCtD
Amphetamine—SLC6A2—nerve—skin cancer	0.00502	0.0349	CbGeAlD
Amphetamine—DRD2—nerve—skin cancer	0.00458	0.0318	CbGeAlD
Amphetamine—Viral infection—Imiquimod—skin cancer	0.00442	0.0149	CcSEcCtD
Amphetamine—Sudden death—Fluorouracil—skin cancer	0.00431	0.0145	CcSEcCtD
Amphetamine—Cardiomyopathy—Fluorouracil—skin cancer	0.00431	0.0145	CcSEcCtD
Amphetamine—Weight decreased—Vismodegib—skin cancer	0.0043	0.0145	CcSEcCtD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—skin cancer	0.00429	0.0481	CbGpPWpGaD
Amphetamine—CARTPT—lymph node—skin cancer	0.00402	0.028	CbGeAlD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00377	0.0422	CbGpPWpGaD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—SYP—skin cancer	0.00371	0.0416	CbGpPWpGaD
Amphetamine—Tooth disorder—Temozolomide—skin cancer	0.00369	0.0124	CcSEcCtD
Amphetamine—Digestion impaired—Temozolomide—skin cancer	0.00358	0.0121	CcSEcCtD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI1—skin cancer	0.00354	0.0397	CbGpPWpGaD
Amphetamine—SLC6A4—Synaptic Vesicle Pathway—SYP—skin cancer	0.00336	0.0376	CbGpPWpGaD
Amphetamine—SLC22A3—nipple—skin cancer	0.00333	0.0231	CbGeAlD
Amphetamine—Injury—Imiquimod—skin cancer	0.00315	0.0106	CcSEcCtD
Amphetamine—MAOB—nipple—skin cancer	0.00308	0.0214	CbGeAlD
Amphetamine—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00306	0.0103	CcSEcCtD
Amphetamine—Cerebrovascular accident—Imiquimod—skin cancer	0.00296	0.00998	CcSEcCtD
Amphetamine—Speech disorder—Temozolomide—skin cancer	0.00278	0.00938	CcSEcCtD
Amphetamine—Irritability—Imiquimod—skin cancer	0.00277	0.00933	CcSEcCtD
Amphetamine—Photosensitivity reaction—Vemurafenib—skin cancer	0.00268	0.00904	CcSEcCtD
Amphetamine—Weight decreased—Vemurafenib—skin cancer	0.00266	0.00896	CcSEcCtD
Amphetamine—Viral infection—Temozolomide—skin cancer	0.00265	0.00894	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.0026	0.00876	CcSEcCtD
Amphetamine—Speech disorder—Fluorouracil—skin cancer	0.00256	0.00865	CcSEcCtD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—SHH—skin cancer	0.00256	0.0287	CbGpPWpGaD
Amphetamine—SLC22A5—nipple—skin cancer	0.00242	0.0168	CbGeAlD
Amphetamine—Dyspepsia—Vismodegib—skin cancer	0.00238	0.00803	CcSEcCtD
Amphetamine—TAAR1—G alpha (s) signalling events—MC1R—skin cancer	0.00237	0.0266	CbGpPWpGaD
Amphetamine—SLC22A3—connective tissue—skin cancer	0.00236	0.0164	CbGeAlD
Amphetamine—Decreased appetite—Vismodegib—skin cancer	0.00235	0.00793	CcSEcCtD
Amphetamine—SLC18A2—female reproductive system—skin cancer	0.00234	0.0162	CbGeAlD
Amphetamine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00233	0.00787	CcSEcCtD
Amphetamine—Fatigue—Vismodegib—skin cancer	0.00233	0.00786	CcSEcCtD
Amphetamine—Constipation—Vismodegib—skin cancer	0.00231	0.0078	CcSEcCtD
Amphetamine—Erectile dysfunction—Imiquimod—skin cancer	0.00231	0.00778	CcSEcCtD
Amphetamine—Photosensitivity reaction—Imiquimod—skin cancer	0.00229	0.00771	CcSEcCtD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00225	0.0252	CbGpPWpGaD
Amphetamine—Injury—Bleomycin—skin cancer	0.00224	0.00756	CcSEcCtD
Amphetamine—Depression—Imiquimod—skin cancer	0.00223	0.00751	CcSEcCtD
Amphetamine—Erythema multiforme—Vemurafenib—skin cancer	0.00222	0.0075	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00221	0.00747	CcSEcCtD
Amphetamine—Gastrointestinal pain—Vismodegib—skin cancer	0.00221	0.00746	CcSEcCtD
Amphetamine—Acute coronary syndrome—Imiquimod—skin cancer	0.0022	0.00743	CcSEcCtD
Amphetamine—Myocardial infarction—Imiquimod—skin cancer	0.00219	0.00738	CcSEcCtD
Amphetamine—MAOB—connective tissue—skin cancer	0.00218	0.0152	CbGeAlD
Amphetamine—Urinary tract infection—Imiquimod—skin cancer	0.00217	0.00732	CcSEcCtD
Amphetamine—Abdominal pain—Vismodegib—skin cancer	0.00214	0.00721	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—CDK4—skin cancer	0.00212	0.0238	CbGpPWpGaD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—skin cancer	0.00211	0.0237	CbGpPWpGaD
Amphetamine—Cerebrovascular accident—Bleomycin—skin cancer	0.0021	0.00709	CcSEcCtD
Amphetamine—Lacosamide—SCN10A—skin cancer	0.00204	0.137	CrCbGaD
Amphetamine—SLC18A2—head—skin cancer	0.00195	0.0136	CbGeAlD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00195	0.0219	CbGpPWpGaD
Amphetamine—SLC22A3—mammalian vulva—skin cancer	0.00194	0.0135	CbGeAlD
Amphetamine—Asthenia—Vismodegib—skin cancer	0.00194	0.00654	CcSEcCtD
Amphetamine—Erythema multiforme—Imiquimod—skin cancer	0.0019	0.00639	CcSEcCtD
Amphetamine—Euphoric mood—Fluorouracil—skin cancer	0.00189	0.00639	CcSEcCtD
Amphetamine—Diarrhoea—Vismodegib—skin cancer	0.00185	0.00624	CcSEcCtD
Amphetamine—MAOB—mammalian vulva—skin cancer	0.0018	0.0125	CbGeAlD
Amphetamine—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00173	0.00583	CcSEcCtD
Amphetamine—Vomiting—Vismodegib—skin cancer	0.00172	0.0058	CcSEcCtD
Amphetamine—Affect lability—Temozolomide—skin cancer	0.00171	0.00577	CcSEcCtD
Amphetamine—Rash—Vismodegib—skin cancer	0.0017	0.00575	CcSEcCtD
Amphetamine—Dermatitis—Vismodegib—skin cancer	0.0017	0.00574	CcSEcCtD
Amphetamine—Anaphylactic shock—Vemurafenib—skin cancer	0.00167	0.00563	CcSEcCtD
Amphetamine—SLC22A3—female reproductive system—skin cancer	0.00166	0.0116	CbGeAlD
Amphetamine—Infection—Vemurafenib—skin cancer	0.00166	0.0056	CcSEcCtD
Amphetamine—Mood swings—Temozolomide—skin cancer	0.00164	0.00555	CcSEcCtD
Amphetamine—SLC6A4—female reproductive system—skin cancer	0.00162	0.0113	CbGeAlD
Amphetamine—Weight decreased—Bleomycin—skin cancer	0.00161	0.00543	CcSEcCtD
Amphetamine—Nausea—Vismodegib—skin cancer	0.00161	0.00542	CcSEcCtD
Amphetamine—Agitation—Imiquimod—skin cancer	0.0016	0.00541	CcSEcCtD
Amphetamine—Angioedema—Imiquimod—skin cancer	0.00159	0.00538	CcSEcCtD
Amphetamine—Blood pressure increased—Docetaxel—skin cancer	0.00159	0.00537	CcSEcCtD
Amphetamine—Acute coronary syndrome—Bleomycin—skin cancer	0.00156	0.00528	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00156	0.00528	CcSEcCtD
Amphetamine—TAAR1—G alpha (s) signalling events—PTGER4—skin cancer	0.00156	0.0175	CbGpPWpGaD
Amphetamine—Myocardial infarction—Bleomycin—skin cancer	0.00155	0.00525	CcSEcCtD
Amphetamine—SLC22A5—skin of body—skin cancer	0.00155	0.0108	CbGeAlD
Amphetamine—Palpitations—Imiquimod—skin cancer	0.00154	0.0052	CcSEcCtD
Amphetamine—MAOB—female reproductive system—skin cancer	0.00154	0.0107	CbGeAlD
Amphetamine—Irritability—Fluorouracil—skin cancer	0.00153	0.00515	CcSEcCtD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—SHH—skin cancer	0.00153	0.0171	CbGpPWpGaD
Amphetamine—Convulsion—Imiquimod—skin cancer	0.00151	0.0051	CcSEcCtD
Amphetamine—Hypertension—Imiquimod—skin cancer	0.00151	0.00508	CcSEcCtD
Amphetamine—Chest pain—Imiquimod—skin cancer	0.00149	0.00501	CcSEcCtD
Amphetamine—Anxiety—Imiquimod—skin cancer	0.00148	0.005	CcSEcCtD
Amphetamine—SLC6A3—head—skin cancer	0.00148	0.0103	CbGeAlD
Amphetamine—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00147	0.00495	CcSEcCtD
Amphetamine—Dry mouth—Imiquimod—skin cancer	0.00145	0.0049	CcSEcCtD
Amphetamine—Decreased appetite—Vemurafenib—skin cancer	0.00145	0.0049	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00144	0.00486	CcSEcCtD
Amphetamine—Fatigue—Vemurafenib—skin cancer	0.00144	0.00486	CcSEcCtD
Amphetamine—Constipation—Vemurafenib—skin cancer	0.00143	0.00482	CcSEcCtD
Amphetamine—SLC6A2—female reproductive system—skin cancer	0.00143	0.00991	CbGeAlD
Amphetamine—Lightheadedness—Docetaxel—skin cancer	0.00142	0.0048	CcSEcCtD
Amphetamine—Infection—Imiquimod—skin cancer	0.00141	0.00477	CcSEcCtD
Amphetamine—SLC22A3—head—skin cancer	0.00139	0.00966	CbGeAlD
Amphetamine—Tachycardia—Imiquimod—skin cancer	0.00139	0.00469	CcSEcCtD
Amphetamine—Erectile dysfunction—Temozolomide—skin cancer	0.00138	0.00466	CcSEcCtD
Amphetamine—Hyperhidrosis—Imiquimod—skin cancer	0.00138	0.00465	CcSEcCtD
Amphetamine—Photosensitivity reaction—Temozolomide—skin cancer	0.00137	0.00462	CcSEcCtD
Amphetamine—SLC18A2—lymph node—skin cancer	0.00137	0.0095	CbGeAlD
Amphetamine—Weight decreased—Temozolomide—skin cancer	0.00136	0.00458	CcSEcCtD
Amphetamine—Anorexia—Imiquimod—skin cancer	0.00136	0.00458	CcSEcCtD
Amphetamine—SLC6A4—head—skin cancer	0.00135	0.00941	CbGeAlD
Amphetamine—Depression—Temozolomide—skin cancer	0.00133	0.0045	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00133	0.00448	CcSEcCtD
Amphetamine—Body temperature increased—Vemurafenib—skin cancer	0.00132	0.00445	CcSEcCtD
Amphetamine—Urinary tract infection—Temozolomide—skin cancer	0.0013	0.00439	CcSEcCtD
Amphetamine—Insomnia—Imiquimod—skin cancer	0.00129	0.00435	CcSEcCtD
Amphetamine—MAOB—head—skin cancer	0.00129	0.00894	CbGeAlD
Amphetamine—Dyspnoea—Imiquimod—skin cancer	0.00127	0.00428	CcSEcCtD
Amphetamine—Somnolence—Imiquimod—skin cancer	0.00127	0.00427	CcSEcCtD
Amphetamine—Photosensitivity reaction—Fluorouracil—skin cancer	0.00126	0.00426	CcSEcCtD
Amphetamine—Erythema multiforme—Dactinomycin—skin cancer	0.00126	0.00424	CcSEcCtD
Amphetamine—Dyspepsia—Imiquimod—skin cancer	0.00125	0.00423	CcSEcCtD
Amphetamine—Decreased appetite—Imiquimod—skin cancer	0.00124	0.00418	CcSEcCtD
Amphetamine—Hypersensitivity—Vemurafenib—skin cancer	0.00123	0.00415	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00123	0.00415	CcSEcCtD
Amphetamine—Fatigue—Imiquimod—skin cancer	0.00123	0.00414	CcSEcCtD
Amphetamine—Acute coronary syndrome—Fluorouracil—skin cancer	0.00122	0.0041	CcSEcCtD
Amphetamine—SLC22A5—female reproductive system—skin cancer	0.00121	0.00841	CbGeAlD
Amphetamine—Myocardial infarction—Fluorouracil—skin cancer	0.00121	0.00408	CcSEcCtD
Amphetamine—Urinary tract infection—Fluorouracil—skin cancer	0.0012	0.00404	CcSEcCtD
Amphetamine—Asthenia—Vemurafenib—skin cancer	0.0012	0.00404	CcSEcCtD
Amphetamine—SLC6A2—head—skin cancer	0.00119	0.00828	CbGeAlD
Amphetamine—TAAR1—GPCR ligand binding—PTCH2—skin cancer	0.00119	0.0133	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Imiquimod—skin cancer	0.00116	0.00393	CcSEcCtD
Amphetamine—Diarrhoea—Vemurafenib—skin cancer	0.00114	0.00386	CcSEcCtD
Amphetamine—Erythema multiforme—Temozolomide—skin cancer	0.00114	0.00383	CcSEcCtD
Amphetamine—Urticaria—Imiquimod—skin cancer	0.00113	0.00382	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00113	0.0127	CbGpPWpGaD
Amphetamine—Body temperature increased—Imiquimod—skin cancer	0.00113	0.0038	CcSEcCtD
Amphetamine—Abdominal pain—Imiquimod—skin cancer	0.00113	0.0038	CcSEcCtD
Amphetamine—Dizziness—Vemurafenib—skin cancer	0.0011	0.00373	CcSEcCtD
Amphetamine—DRD2—head—skin cancer	0.00109	0.00755	CbGeAlD
Amphetamine—Vomiting—Vemurafenib—skin cancer	0.00106	0.00358	CcSEcCtD
Amphetamine—Chest pain—Bleomycin—skin cancer	0.00106	0.00356	CcSEcCtD
Amphetamine—Abdominal pain upper—Docetaxel—skin cancer	0.00105	0.00356	CcSEcCtD
Amphetamine—Rash—Vemurafenib—skin cancer	0.00105	0.00355	CcSEcCtD
Amphetamine—Dermatitis—Vemurafenib—skin cancer	0.00105	0.00355	CcSEcCtD
Amphetamine—Hypersensitivity—Imiquimod—skin cancer	0.00105	0.00354	CcSEcCtD
Amphetamine—Headache—Vemurafenib—skin cancer	0.00105	0.00353	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00104	0.00351	CcSEcCtD
Amphetamine—Asthenia—Imiquimod—skin cancer	0.00102	0.00345	CcSEcCtD
Amphetamine—Anaphylactic shock—Bleomycin—skin cancer	0.00101	0.00341	CcSEcCtD
Amphetamine—Infection—Bleomycin—skin cancer	0.00101	0.00339	CcSEcCtD
Amphetamine—Nausea—Vemurafenib—skin cancer	0.000992	0.00335	CcSEcCtD
Amphetamine—Tremor—Temozolomide—skin cancer	0.00098	0.00331	CcSEcCtD
Amphetamine—Diarrhoea—Imiquimod—skin cancer	0.000974	0.00329	CcSEcCtD
Amphetamine—SLC22A3—lymph node—skin cancer	0.000974	0.00677	CbGeAlD
Amphetamine—Anorexia—Bleomycin—skin cancer	0.000964	0.00325	CcSEcCtD
Amphetamine—Agitation—Temozolomide—skin cancer	0.000961	0.00324	CcSEcCtD
Amphetamine—Angioedema—Temozolomide—skin cancer	0.000955	0.00322	CcSEcCtD
Amphetamine—Dizziness—Imiquimod—skin cancer	0.000942	0.00318	CcSEcCtD
Amphetamine—Infection—Dactinomycin—skin cancer	0.000937	0.00316	CcSEcCtD
Amphetamine—Palpitations—Temozolomide—skin cancer	0.000924	0.00312	CcSEcCtD
Amphetamine—Convulsion—Temozolomide—skin cancer	0.000906	0.00306	CcSEcCtD
Amphetamine—Vomiting—Imiquimod—skin cancer	0.000905	0.00306	CcSEcCtD
Amphetamine—Weight decreased—Docetaxel—skin cancer	0.000903	0.00305	CcSEcCtD
Amphetamine—Hypertension—Temozolomide—skin cancer	0.000903	0.00305	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—skin cancer	0.000902	0.0101	CbGpPWpGaD
Amphetamine—Dyspnoea—Bleomycin—skin cancer	0.000902	0.00304	CcSEcCtD
Amphetamine—MAOB—lymph node—skin cancer	0.000901	0.00626	CbGeAlD
Amphetamine—Anorexia—Dactinomycin—skin cancer	0.000899	0.00303	CcSEcCtD
Amphetamine—Rash—Imiquimod—skin cancer	0.000898	0.00303	CcSEcCtD
Amphetamine—Dermatitis—Imiquimod—skin cancer	0.000897	0.00303	CcSEcCtD
Amphetamine—Headache—Imiquimod—skin cancer	0.000892	0.00301	CcSEcCtD
Amphetamine—Anxiety—Temozolomide—skin cancer	0.000887	0.00299	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000882	0.00298	CcSEcCtD
Amphetamine—Decreased appetite—Bleomycin—skin cancer	0.000879	0.00297	CcSEcCtD
Amphetamine—Acute coronary syndrome—Docetaxel—skin cancer	0.000877	0.00296	CcSEcCtD
Amphetamine—Myocardial infarction—Docetaxel—skin cancer	0.000872	0.00294	CcSEcCtD
Amphetamine—Dry mouth—Temozolomide—skin cancer	0.000871	0.00294	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—MC1R—skin cancer	0.000861	0.00964	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Temozolomide—skin cancer	0.000853	0.00288	CcSEcCtD
Amphetamine—Infection—Temozolomide—skin cancer	0.000848	0.00286	CcSEcCtD
Amphetamine—Nausea—Imiquimod—skin cancer	0.000846	0.00285	CcSEcCtD
Amphetamine—Convulsion—Fluorouracil—skin cancer	0.000835	0.00282	CcSEcCtD
Amphetamine—SLC6A2—lymph node—skin cancer	0.000834	0.0058	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—IL6—skin cancer	0.000826	0.00925	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Temozolomide—skin cancer	0.000825	0.00278	CcSEcCtD
Amphetamine—Chest pain—Fluorouracil—skin cancer	0.00082	0.00277	CcSEcCtD
Amphetamine—Decreased appetite—Dactinomycin—skin cancer	0.00082	0.00277	CcSEcCtD
Amphetamine—Fatigue—Dactinomycin—skin cancer	0.000813	0.00274	CcSEcCtD
Amphetamine—Anorexia—Temozolomide—skin cancer	0.000813	0.00274	CcSEcCtD
Amphetamine—Urticaria—Bleomycin—skin cancer	0.000804	0.00271	CcSEcCtD
Amphetamine—Body temperature increased—Bleomycin—skin cancer	0.0008	0.0027	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000788	0.00882	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Fluorouracil—skin cancer	0.000786	0.00265	CcSEcCtD
Amphetamine—Infection—Fluorouracil—skin cancer	0.000781	0.00264	CcSEcCtD
Amphetamine—CYP2D6—female reproductive system—skin cancer	0.000781	0.00543	CbGeAlD
Amphetamine—Insomnia—Temozolomide—skin cancer	0.000772	0.0026	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000772	0.0026	CcSEcCtD
Amphetamine—Tachycardia—Fluorouracil—skin cancer	0.000767	0.00259	CcSEcCtD
Amphetamine—Dyspnoea—Temozolomide—skin cancer	0.000761	0.00257	CcSEcCtD
Amphetamine—Somnolence—Temozolomide—skin cancer	0.000759	0.00256	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—NKX2-1—skin cancer	0.000757	0.00848	CbGpPWpGaD
Amphetamine—Erythema multiforme—Docetaxel—skin cancer	0.000755	0.00255	CcSEcCtD
Amphetamine—Dyspepsia—Temozolomide—skin cancer	0.000751	0.00253	CcSEcCtD
Amphetamine—Anorexia—Fluorouracil—skin cancer	0.000749	0.00253	CcSEcCtD
Amphetamine—Abdominal pain—Dactinomycin—skin cancer	0.000746	0.00252	CcSEcCtD
Amphetamine—Body temperature increased—Dactinomycin—skin cancer	0.000746	0.00252	CcSEcCtD
Amphetamine—Hypersensitivity—Bleomycin—skin cancer	0.000745	0.00251	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000743	0.00833	CbGpPWpGaD
Amphetamine—Decreased appetite—Temozolomide—skin cancer	0.000742	0.0025	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—RHOU—skin cancer	0.000739	0.00828	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000737	0.00249	CcSEcCtD
Amphetamine—Fatigue—Temozolomide—skin cancer	0.000736	0.00248	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—skin cancer	0.000734	0.00823	CbGpPWpGaD
Amphetamine—Constipation—Temozolomide—skin cancer	0.00073	0.00246	CcSEcCtD
Amphetamine—Asthenia—Bleomycin—skin cancer	0.000726	0.00245	CcSEcCtD
Amphetamine—Insomnia—Fluorouracil—skin cancer	0.000711	0.0024	CcSEcCtD
Amphetamine—SLC22A5—lymph node—skin cancer	0.000708	0.00492	CbGeAlD
Amphetamine—Dyspnoea—Fluorouracil—skin cancer	0.000701	0.00237	CcSEcCtD
Amphetamine—Somnolence—Fluorouracil—skin cancer	0.000699	0.00236	CcSEcCtD
Amphetamine—Gastrointestinal pain—Temozolomide—skin cancer	0.000698	0.00235	CcSEcCtD
Amphetamine—Hypersensitivity—Dactinomycin—skin cancer	0.000695	0.00235	CcSEcCtD
Amphetamine—Dyspepsia—Fluorouracil—skin cancer	0.000692	0.00234	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000686	0.00769	CbGpPWpGaD
Amphetamine—Decreased appetite—Fluorouracil—skin cancer	0.000684	0.00231	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000681	0.00763	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000679	0.0076	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000679	0.00229	CcSEcCtD
Amphetamine—Urticaria—Temozolomide—skin cancer	0.000678	0.00229	CcSEcCtD
Amphetamine—Asthenia—Dactinomycin—skin cancer	0.000677	0.00228	CcSEcCtD
Amphetamine—Abdominal pain—Temozolomide—skin cancer	0.000675	0.00228	CcSEcCtD
Amphetamine—Body temperature increased—Temozolomide—skin cancer	0.000675	0.00228	CcSEcCtD
Amphetamine—CYP2D6—head—skin cancer	0.000652	0.00453	CbGeAlD
Amphetamine—Diarrhoea—Dactinomycin—skin cancer	0.000646	0.00218	CcSEcCtD
Amphetamine—Vomiting—Bleomycin—skin cancer	0.000643	0.00217	CcSEcCtD
Amphetamine—Rash—Bleomycin—skin cancer	0.000638	0.00215	CcSEcCtD
Amphetamine—Dermatitis—Bleomycin—skin cancer	0.000637	0.00215	CcSEcCtD
Amphetamine—Hypersensitivity—Temozolomide—skin cancer	0.000629	0.00212	CcSEcCtD
Amphetamine—Urticaria—Fluorouracil—skin cancer	0.000625	0.00211	CcSEcCtD
Amphetamine—Body temperature increased—Fluorouracil—skin cancer	0.000622	0.0021	CcSEcCtD
Amphetamine—Palpitations—Docetaxel—skin cancer	0.000614	0.00207	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—SHH—skin cancer	0.000613	0.00687	CbGpPWpGaD
Amphetamine—Asthenia—Temozolomide—skin cancer	0.000612	0.00207	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—PTCH2—skin cancer	0.000611	0.00684	CbGpPWpGaD
Amphetamine—Convulsion—Docetaxel—skin cancer	0.000602	0.00203	CcSEcCtD
Amphetamine—Nausea—Bleomycin—skin cancer	0.000601	0.00203	CcSEcCtD
Amphetamine—Hypertension—Docetaxel—skin cancer	0.0006	0.00203	CcSEcCtD
Amphetamine—Vomiting—Dactinomycin—skin cancer	0.0006	0.00202	CcSEcCtD
Amphetamine—Rash—Dactinomycin—skin cancer	0.000595	0.00201	CcSEcCtD
Amphetamine—Chest pain—Docetaxel—skin cancer	0.000592	0.002	CcSEcCtD
Amphetamine—Diarrhoea—Temozolomide—skin cancer	0.000584	0.00197	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—SMO—skin cancer	0.000581	0.00651	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—PTCH1—skin cancer	0.000581	0.00651	CbGpPWpGaD
Amphetamine—Hypersensitivity—Fluorouracil—skin cancer	0.000579	0.00195	CcSEcCtD
Amphetamine—Dry mouth—Docetaxel—skin cancer	0.000579	0.00195	CcSEcCtD
Amphetamine—Anaphylactic shock—Docetaxel—skin cancer	0.000568	0.00191	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—PTGER4—skin cancer	0.000566	0.00634	CbGpPWpGaD
Amphetamine—Dizziness—Temozolomide—skin cancer	0.000564	0.0019	CcSEcCtD
Amphetamine—Infection—Docetaxel—skin cancer	0.000564	0.0019	CcSEcCtD
Amphetamine—Nausea—Dactinomycin—skin cancer	0.00056	0.00189	CcSEcCtD
Amphetamine—Tachycardia—Docetaxel—skin cancer	0.000554	0.00187	CcSEcCtD
Amphetamine—Vomiting—Temozolomide—skin cancer	0.000543	0.00183	CcSEcCtD
Amphetamine—Anorexia—Docetaxel—skin cancer	0.000541	0.00183	CcSEcCtD
Amphetamine—Rash—Temozolomide—skin cancer	0.000538	0.00182	CcSEcCtD
Amphetamine—Diarrhoea—Fluorouracil—skin cancer	0.000538	0.00182	CcSEcCtD
Amphetamine—Dermatitis—Temozolomide—skin cancer	0.000538	0.00181	CcSEcCtD
Amphetamine—Headache—Temozolomide—skin cancer	0.000535	0.0018	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00053	0.00594	CbGpPWpGaD
Amphetamine—Dizziness—Fluorouracil—skin cancer	0.00052	0.00175	CcSEcCtD
Amphetamine—Insomnia—Docetaxel—skin cancer	0.000513	0.00173	CcSEcCtD
Amphetamine—Nausea—Temozolomide—skin cancer	0.000507	0.00171	CcSEcCtD
Amphetamine—Dyspnoea—Docetaxel—skin cancer	0.000506	0.00171	CcSEcCtD
Amphetamine—Somnolence—Docetaxel—skin cancer	0.000505	0.0017	CcSEcCtD
Amphetamine—Vomiting—Fluorouracil—skin cancer	0.0005	0.00169	CcSEcCtD
Amphetamine—Dyspepsia—Docetaxel—skin cancer	0.0005	0.00169	CcSEcCtD
Amphetamine—Rash—Fluorouracil—skin cancer	0.000496	0.00167	CcSEcCtD
Amphetamine—Dermatitis—Fluorouracil—skin cancer	0.000495	0.00167	CcSEcCtD
Amphetamine—Decreased appetite—Docetaxel—skin cancer	0.000493	0.00166	CcSEcCtD
Amphetamine—Headache—Fluorouracil—skin cancer	0.000493	0.00166	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00049	0.00165	CcSEcCtD
Amphetamine—Fatigue—Docetaxel—skin cancer	0.000489	0.00165	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—MC1R—skin cancer	0.000486	0.00545	CbGpPWpGaD
Amphetamine—Constipation—Docetaxel—skin cancer	0.000485	0.00164	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000469	0.00526	CbGpPWpGaD
Amphetamine—Nausea—Fluorouracil—skin cancer	0.000467	0.00158	CcSEcCtD
Amphetamine—Gastrointestinal pain—Docetaxel—skin cancer	0.000464	0.00157	CcSEcCtD
Amphetamine—DRD2—Circadian rythm related genes—NKX2-1—skin cancer	0.000463	0.00519	CbGpPWpGaD
Amphetamine—Body temperature increased—Docetaxel—skin cancer	0.000449	0.00151	CcSEcCtD
Amphetamine—Abdominal pain—Docetaxel—skin cancer	0.000449	0.00151	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—MC1R—skin cancer	0.000442	0.00495	CbGpPWpGaD
Amphetamine—Hypersensitivity—Docetaxel—skin cancer	0.000418	0.00141	CcSEcCtD
Amphetamine—Asthenia—Docetaxel—skin cancer	0.000407	0.00137	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.0004	0.00448	CbGpPWpGaD
Amphetamine—Diarrhoea—Docetaxel—skin cancer	0.000388	0.00131	CcSEcCtD
Amphetamine—Dizziness—Docetaxel—skin cancer	0.000375	0.00127	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—PTCH2—skin cancer	0.000361	0.00404	CbGpPWpGaD
Amphetamine—Vomiting—Docetaxel—skin cancer	0.000361	0.00122	CcSEcCtD
Amphetamine—Rash—Docetaxel—skin cancer	0.000358	0.00121	CcSEcCtD
Amphetamine—Dermatitis—Docetaxel—skin cancer	0.000357	0.00121	CcSEcCtD
Amphetamine—Headache—Docetaxel—skin cancer	0.000356	0.0012	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000346	0.00388	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000345	0.00386	CbGpPWpGaD
Amphetamine—Nausea—Docetaxel—skin cancer	0.000337	0.00114	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—PTGER4—skin cancer	0.00032	0.00358	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—SHH—skin cancer	0.000315	0.00353	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000308	0.00345	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PTCH1—skin cancer	0.000298	0.00334	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—SMO—skin cancer	0.000298	0.00334	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PTGER4—skin cancer	0.00029	0.00325	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTCH2—skin cancer	0.000278	0.00311	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GLI2—skin cancer	0.000274	0.00306	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000269	0.00302	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000264	0.00295	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MC1R—skin cancer	0.000261	0.00292	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GLI1—skin cancer	0.000257	0.00288	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—skin cancer	0.000245	0.00274	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SUFU—skin cancer	0.000244	0.00273	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—skin cancer	0.000242	0.00271	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000239	0.00267	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—CDK4—skin cancer	0.000213	0.00239	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000202	0.00227	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PLIN2—skin cancer	0.000202	0.00226	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—MC1R—skin cancer	0.000201	0.00225	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SHH—skin cancer	0.000186	0.00208	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—BRAF—skin cancer	0.000186	0.00208	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RASA1—skin cancer	0.000185	0.00207	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SMO—skin cancer	0.000176	0.00197	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTCH1—skin cancer	0.000176	0.00197	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000173	0.00194	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RHOU—skin cancer	0.000172	0.00193	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTGER4—skin cancer	0.000172	0.00192	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PLIN2—skin cancer	0.000171	0.00192	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CSPG4—skin cancer	0.000163	0.00182	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FOXO4—skin cancer	0.000152	0.0017	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	0.000144	0.00162	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—SHH—skin cancer	0.000143	0.0016	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTCH2—skin cancer	0.000142	0.0016	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CSPG4—skin cancer	0.000138	0.00154	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTCH1—skin cancer	0.000136	0.00152	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—SMO—skin cancer	0.000136	0.00152	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTGER4—skin cancer	0.000132	0.00148	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CDK4—skin cancer	0.00013	0.00146	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—MC1R—skin cancer	0.000113	0.00127	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—skin cancer	0.000111	0.00125	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ENO2—skin cancer	0.000111	0.00124	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—BRAF—skin cancer	0.000111	0.00124	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MC1R—skin cancer	0.000103	0.00115	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—skin cancer	0.000102	0.00114	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TERT—skin cancer	0.000101	0.00113	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLIN2—skin cancer	9.85e-05	0.0011	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ENO2—skin cancer	9.37e-05	0.00105	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—skin cancer	9.07e-05	0.00102	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—NRAS—skin cancer	8.53e-05	0.000956	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—HRAS—skin cancer	8.53e-05	0.000955	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTCH2—skin cancer	8.42e-05	0.000943	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—skin cancer	8.3e-05	0.00093	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—BRAF—skin cancer	8.02e-05	0.000898	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CSPG4—skin cancer	7.94e-05	0.000889	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PTGER4—skin cancer	7.46e-05	0.000836	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—skin cancer	7.34e-05	0.000822	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SHH—skin cancer	7.34e-05	0.000822	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTCH1—skin cancer	6.96e-05	0.00078	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SMO—skin cancer	6.96e-05	0.00078	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTGER4—skin cancer	6.77e-05	0.000759	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	6.64e-05	0.000743	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ERCC2—skin cancer	6.43e-05	0.000721	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GLI2—skin cancer	6.38e-05	0.000715	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—skin cancer	6.24e-05	0.000699	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MC1R—skin cancer	6.09e-05	0.000682	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GLI1—skin cancer	6e-05	0.000672	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—skin cancer	5.97e-05	0.000669	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SUFU—skin cancer	5.69e-05	0.000637	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—skin cancer	5.55e-05	0.000622	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLIN2—skin cancer	5.52e-05	0.000619	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ERCC2—skin cancer	5.44e-05	0.00061	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO2—skin cancer	5.39e-05	0.000604	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—skin cancer	5.08e-05	0.00057	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—skin cancer	5.08e-05	0.000569	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—skin cancer	5.04e-05	0.000564	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CSPG4—skin cancer	4.45e-05	0.000499	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—skin cancer	4.34e-05	0.000486	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SHH—skin cancer	4.34e-05	0.000486	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RASA1—skin cancer	4.31e-05	0.000483	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTCH1—skin cancer	4.11e-05	0.000461	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMO—skin cancer	4.11e-05	0.000461	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTGER4—skin cancer	4e-05	0.000448	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—skin cancer	3.86e-05	0.000432	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—skin cancer	3.85e-05	0.000432	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—skin cancer	3.69e-05	0.000413	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FOXO4—skin cancer	3.53e-05	0.000396	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—skin cancer	3.53e-05	0.000395	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—skin cancer	3.26e-05	0.000366	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ERCC2—skin cancer	3.13e-05	0.000351	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO2—skin cancer	3.03e-05	0.000339	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—skin cancer	2.36e-05	0.000265	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—skin cancer	1.99e-05	0.000223	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—skin cancer	1.88e-05	0.00021	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BRAF—skin cancer	1.87e-05	0.000209	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ERCC2—skin cancer	1.76e-05	0.000197	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—skin cancer	1.71e-05	0.000192	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—skin cancer	1.46e-05	0.000163	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—skin cancer	1.39e-05	0.000156	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—skin cancer	1.18e-05	0.000132	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—skin cancer	1.05e-05	0.000118	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—skin cancer	1.01e-05	0.000113	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—skin cancer	8.99e-06	0.000101	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—skin cancer	8.6e-06	9.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—skin cancer	8.23e-06	9.22e-05	CbGpPWpGaD
